Rapid Readouts: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up

July 8, 2021 | Alan Skarbnik, MD

Share on:
View More
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    View More
    Current Time 0:00
    Duration 0:00
    Loaded: 0%
    Stream Type LIVE
    Remaining Time 0:00
     
    1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Alan Skarbnik, MD, presents data from the 2021 American Society of Clinical Oncology annual meeting on the ELEVATE-TN trial four-year follow up of chronic lymphocytic leukemia patients treated with acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil